(GNB Desk): Johnson & Johnson’s single-dose vaccine is 72 percent effective in preventing Covid-19 in the United States, but a lower rate of 66 per cent was observed globally in the large trial conducted across three continents and against multiple variants the drugmaker has confirmed today. The study was conducted in the U.S., Latin America, and South Africa.
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe Covid-19 was 66 per cent in Latin America and just 57 per cent in South Africa, where a new variant of the virus is circulating.
The vaccine did demonstrate complete protection against COVID-19 serious enough to require hospitalization, according to a news release from the company. The vaccine was 85% percent effective in preventing severe forms of the disease.
The company says it plans to apply to the Food and Drug Administration for emergency use authorization to distribute the vaccine.
The Johnson & Johnson vaccine is given as a single shot, unlike the vaccines from Moderna and Pfizer that require two shots given weeks apart. The Johnson & Johnson vaccine also doesn’t require ultracold storage.
A global media for the latest news, entertainment, music fashion, and more.
